Methods for modifying PRO instruments for clinical practice and clinical research use
This webinar will describe the steps that the speakers have used in producing symptom and function measure to answer specific questions that emerge in clinical practice and research. The webinar will also consider such issues as the incorporation of PROs into clinical practice, the issue of patient and clinician burden, the determination of whether or not PRO results can be incorporated into actionable steps. The speakers will present an example of modification of a validated tool to meet the need for use in clinical research and care in patients with malignant pleural mesothelioma, a relatively rare but highly symptomatic condition.
As the field of oncology evolves, the development of patient-reported outcomes (PRO) must also adapt to the changing benefits and toxicities that emerge with new therapies. It is always possible to develop de novo instruments, but that process can be time consuming and expensive. An alternative is to adapt existing PROs so that they meet the requirements of clinical practice and research. Several guidelines have emerged for PRO development and use including the Food and Drug Administration PRO guidance and ISOQOL recommendations.
After the webinar, the learner will be able to:
- Describe the relative benefits of de novo development versus modification of an existing measure.
- Describe the steps needed in modification to meet various PRO guidelines.
- Charles Cleeland, PhD, McCullough Professor of Cancer Research, MD Anderson Cancer Center
- Tito R. Mendoza, PhD, Professor, MD Anderson Cancer Center
Xin Shelley Wang, MD, MPH, MD Anderson Cancer Center
ISOQOL Webinar Committee – A subcommittee of the Education Committee